MindWalk Holdings (HYFT) Net Income (2020 - 2026)
MindWalk Holdings (HYFT) posted quarterly Net Income of $930.12 for Q2 2026, down 99.9% year-over-year from $895979.1 in Q2 2025, and down 99.97% quarter-over-quarter from $2.8 million in Q1 2026.
MindWalk Holdings (HYFT) Net Income (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Net Income for 7 consecutive years, with $930.12 the latest figure, recorded in Q2 2026.
- In Q2 2026, Net Income fell 99.9% year-over-year to $930.12; the TTM figure through Apr 2026 stood at $7.2 million (down 65.23% YoY), while the FY2026 annual figure was $841120.4, down 59.78% from the prior year.
- Net Income eased to $930.12 in Q2 2026 per HYFT's latest filing, from $2.8 million in the prior quarter.
- Across five years, Net Income topped out at $15.2 million in Q1 2025 and bottomed at -$32.9 million in Q2 2023.
- Historically, Net Income has averaged -$1.9 million across 5 years, with a median of $1.8 million in 2024.
- On a YoY basis, Net Income climbed as much as 91044.99% in 2022 and fell as far as 328.73% in 2022.
- MindWalk Holdings' Net Income stood at $3.9 million in 2022, then tumbled by 54.81% to $1.8 million in 2023, then grew by 5.14% to $1.9 million in 2024, then jumped by 251.39% to $6.6 million in 2025, then plunged by 99.99% to $930.12 in 2026.
- Business Quant data shows HYFT's Net Income at $930.12 in Q2 2026, $2.8 million in Q1 2026, and $6.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -290.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 930.12 |
| Jan 31, 2026 | 2.83 Mn |
| Oct 31, 2025 | 6.57 Mn |
| Jul 31, 2025 | -2.15 Mn |
| Apr 30, 2025 | 895,979.08 |
| Jan 31, 2025 | 15.16 Mn |
| Oct 31, 2024 | 1.87 Mn |
| Jul 31, 2024 | 2.92 Mn |
| Apr 30, 2024 | -27.69 Mn |
| Jan 31, 2024 | 1.98 Mn |
| Oct 31, 2023 | 1.78 Mn |
| Jul 31, 2023 | 2.56 Mn |
| Apr 30, 2023 | -32.91 Mn |
| Jan 31, 2023 | 3.48 Mn |
| Oct 31, 2022 | 3.93 Mn |
| Jul 31, 2022 | 304,605.58 |
| Apr 30, 2022 | -15.40 Mn |
| Jan 31, 2022 | -167,410.40 |
| Oct 31, 2021 | -4,326.39 |
| Jul 31, 2021 | -2,568.93 |